Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Dow
McKinsey
Express Scripts
AstraZeneca
Harvard Business School

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207356

See Plans and Pricing

« Back to Dashboard

NDA 207356 describes ARIKAYCE KIT, which is a drug marketed by Insmed Inc and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the ARIKAYCE KIT profile page.

The generic ingredient in ARIKAYCE KIT is amikacin sulfate. There are fifteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the amikacin sulfate profile page.
Summary for 207356
Tradename:ARIKAYCE KIT
Applicant:Insmed Inc
Ingredient:amikacin sulfate
Patents:10
Formulation / Manufacturing:see details
Pharmacology for NDA: 207356
Medical Subject Heading (MeSH) Categories for 207356
Suppliers and Packaging for NDA: 207356
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ARIKAYCE KIT amikacin sulfate SUSPENSION, LIPOSOMAL;INHALATION 207356 NDA Insmed Incorporated 71558-590 71558-590-28 28 VIAL in 1 CARTON (71558-590-28) > 8.4 mL in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION, LIPOSOMAL;INHALATIONStrengthEQ 590MG BASE/8.4ML
Approval Date:Sep 28, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 28, 2030
Regulatory Exclusivity Use:GENERATING ANTIBIOTIC INCENTIVES NOW
Regulatory Exclusivity Expiration:Sep 28, 2025
Regulatory Exclusivity Use:TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNATIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
Patent:  Start TrialPatent Expiration:May 15, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION DRUG REGIMEN

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Dow
Mallinckrodt
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.